Dr Qazilbash speaks with ecancer at the ASH 2017 annual meeting about the outcomes of a phase III trial of melphalan with busulfan as induction therapy for multiple myeloma patients.
He outlines the current schedule of induction therapy, and improvements in response duration and progression-free survival seen in the experimental arm.
Dr Qazilbash also describes the increased toxicity as reversible, and with no particularly vulnerable patient group, recommending the combination for further evaluation in larger trials.
ecancer’s filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.